文献速递肿瘤 PET/CT

肾细胞癌患者术前18F-FDG PET/CT代谢肿瘤体积与总病灶糖酵解的预后价值

Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative 18F-FDG PET/CT in Patients With Renal Cell Carcinoma.
PubMed 文献 · Clin Nucl Med · 2017-01-01

回顾性分析139例肾细胞癌患者术前FDG PET/CT,随访期间24例(17%)出现疾病进展。单因素分析显示年龄、pTNM分期、Fuhrman分级、微观淋巴和静脉侵犯、SUVmax、MTV及TLG均为PFS的显著预后因素(P<0.05)。多因素分析显示MTV、TLG及高pTNM分期是PFS的独立显著预测因子。

要点

  • 术前MTV、TLG及高pTNM分期是肾细胞癌PFS的独立显著预测因子。
  • 139例中24例(17%)随访期间出现疾病进展。
  • 单因素分析中年龄、pTNM分期、Fuhrman分级、微观淋巴和静脉侵犯、SUVmax、MTV、TLG均与PFS显著相关(P<0.05)。

核心结论

  • 术前MTV、TLG及高pTNM分期是肾细胞癌患者PFS的显著预后因素。

研究设计与样本

  • 回顾性分析139例接受肿瘤切除术前FDG PET/CT检查的肾细胞癌患者。

主要发现

  • 139例患者中24例(17%)随访期间出现疾病进展。
  • 单因素分析显示年龄、pTNM分期、Fuhrman分级、微观淋巴和静脉侵犯、SUVmax、MTV及TLG均为PFS的显著预后因素(P<0.05)。
  • 多因素分析显示MTV(P=0.02;HR 9.5;95%CI 1.50-187.0)、TLG(P=0.02;HR 9.0;95%CI 1.40-178.5)及高pTNM分期(P=0.004;HR 5.9;95%CI 1.66-20.4)是PFS的显著预测因子。

关键数值与推荐

  • MTV多因素分析:P=0.02,HR 9.5,95%CI 1.50-187.0。
  • TLG多因素分析:P=0.02,HR 9.0,95%CI 1.40-178.5。
  • 高pTNM分期多因素分析:P=0.004,HR 5.9,95%CI 1.66-20.4。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We evaluated the prognostic value of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) measured using pretreatment F-FDG PET/CT in patients with renal cell carcinoma (RCC). METHODS: A total of 139 patients with RCC who had undergone FDG PET/CT before tumor resection were retrospectively reviewed. We determined the SUVmax, MTV, and TLG and compared the results obtained with those required for a progression-free survival (PFS), which was defined as disease progression. Receiver operating characteristic curve analysis was used to compare prediction accuracies. Univariate and multivariate analyses of conventional clinicopathologic variables (age, sex, pathological tumor node metastasis [pTNM] stage, histological type, Fuhrman grade, and presence/absence of microscopic lymphatic and venous invasions) were used to compare the reliability of the metabolic parameters (SUVmax, MTV, and TLG). RESULTS: Of the 139 patients, 24 patients (17%) experienced disease progression during the follow-up period. The age, pTNM stage, Fuhrman grade, presence/absence of microscopic lymphatic and venous invasions, SUVmax, MTV, and TLG were found to be significant prognostic factors for PFS (P < 0.05) on univariate analyses. Multivariate analyses revealed that MTV, TLG, and high pTNM stage (P = 0.02 [hazard ratio, 9.5; 95% confidence interval, 1.50-187.0], P = 0.02 [hazard ratio, 9.0; 95% confidence interval, 1.40-178.5], P = 0.004 [hazard ratio, 5.9; 95% confidence interval, 1.66-20.4], respectively) were the significant predictors after adjustment for other variables of PFS. CONCLUSION: The pretreatment value of MTV, TLG, and high pTNM stage are the significant prognostic factors in patients with RCC.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Nakajima R, Matsuo Y, Kondo T, et al. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative 18F-FDG PET/CT in Patients With Renal Cell Carcinoma. Clin Nucl Med. 2017. PMID: 28134692. doi:10.1097/RLU.0000000000001552

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。